Home/Filings/4/0001415889-25-015383
4//SEC Filing

Harsch Mutya 4

Accession 0001415889-25-015383

CIK 0001566044other

Filed

Jun 2, 8:00 PM ET

Accepted

Jun 3, 4:15 PM ET

Size

5.5 KB

Accession

0001415889-25-015383

Insider Transaction Report

Form 4
Period: 2025-06-02
Harsch Mutya
CHIEF LEGAL OFFICER AND GC
Transactions
  • Award

    Common Stock

    2025-06-02$0.81/sh+1,145$927136,646 total
Footnotes (1)
  • [F1]These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ending on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 30, 2025 (the last trading day of the offering period).

Issuer

VYNE Therapeutics Inc.

CIK 0001566044

Entity typeother

Related Parties

1
  • filerCIK 0001727809

Filing Metadata

Form type
4
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 4:15 PM ET
Size
5.5 KB